PLoS ONE (Jan 2011)

Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis.

  • Matheus Correa-Costa,
  • Tarcio Teodoro Braga,
  • Patricia Semedo,
  • Caroline Yuri Hayashida,
  • Luiz Roberto Grassmann Bechara,
  • Rosa Maria Elias,
  • Claudiene Rodrigues Barreto,
  • Claudia Silva-Cunha,
  • Meire Ioshie Hyane,
  • Giselle Martins Gonçalves,
  • Patricia Chakur Brum,
  • Clarice Fujihara,
  • Roberto Zatz,
  • Alvaro Pacheco-Silva,
  • Dario S Zamboni,
  • Niels Olsen Saraiva Camara

DOI
https://doi.org/10.1371/journal.pone.0029004
Journal volume & issue
Vol. 6, no. 12
p. e29004

Abstract

Read online

Tubule-interstitial nephritis (TIN) results in decreased renal function and interstitial inflammation, which ultimately leads to fibrosis. Excessive adenine intake can cause TIN because xanthine dehydrogenase (XDH) can convert this purine into an insoluble compound, which precipitates in the tubuli. Innate immune sensors, such as Toll-like receptors (TLR) and inflammasome complex, play a crucial role in the initiation of inflammation. The aim of this study was to evaluate the roles of TLR-2 and -4, Myd88 and inflammasome complex in an experimental model of TIN. Here, we show that wild-type (WT) mice fed adenine-enriched food exhibited significant renal dysfunction and enhanced cellular infiltration accompanied by collagen deposition. They also presented higher gene and protein expression of pro-inflammatory cytokines. In contrast, TLR-2, -4, MyD88, ASC and Caspase-1 KO mice showed renoprotection associated with expression of inflammatory molecules at levels comparable to controls. Furthermore, treatment of WT animals with allopurinol, an XDH inhibitor, led to reduced levels of uric acid, oxidative stress, collagen deposition and a downregulation of the NF-kB signaling pathway. We concluded that MyD88 signaling and inflammasome participate in the development of TIN. Furthermore, inhibition of XDH seems to be a promising way to therapeutically target the developing inflammatory process.